Biotech | August 25, 2021
Carbogen Amcis AG signs co-investment agreement
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
It is the first branded generic alternative to Fostair 100/6 pMDI
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
This brings hope for patients suffering from all types of hernia, as the centre has a replenished armamentarium of technology and techniques to produce a good outcome
The acquisition expands the company’s service portfolio in the transition care segment
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
The MoU was signed on World Organ Donation Day which falls on August 13
Subscribe To Our Newsletter & Stay Updated
